Insight journal - Technology

Molecular diagnostics partnering: recent life science trends 2009-2014

Posted on 08 October 2014

Tags: , , ,

Molecular diagnostics is the use of molecular biology for medical testing and clinical applications. This discipline determines how genes and proteins interact in a cell. This partnering article reflects on the recent life science trends in the molecular diagnostics technology arena.

According to the Current Agreements life science deals and alliance database, around 3,000 molecular diagnostics partnering deals were announced since 2009.

The Molecular Diagnostics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals covering the following types of molecular diagnostics:

The following figure shows overall molecular diagnostics partnering frequency between 2009 and August 2014.

Figure 1: Molecular diagnostics partnering since 2009









Source: Current Agreements, 2014

Molecular diagnostics technology has been rapidly gaining popularity owing to its advancements on several clinical applications. From the graph below, you can say that molecular diagnostics partnering has also observed an increasing frequency since 2009 with a peak in 2011 with the announcement of 156 deals.

A useful means of understanding best practice in molecular diagnostics dealmaking is to follow the activities and deal terms used by the most active companies in a certain type of deal.

The following is a list of the most active molecular diagnostics dealmakers since 2009. Suprisingly, big pharma companies have not penetrated into molecular diagnostics dealmaking.

Figure 2: Molecular diagnostics partnering leading dealmakers since 2009











Source: Current Agreements, 2014

Recently in 2013, Qiagen and Exosome Diagnostics announced a strategic collaboration to develop non-invasive molecular diagnostics in monitoring genetic mutations in lung cancer patients. Read the entire deal here.

Most of the deals entered into by molecular diagnostics are collaborative R&D or licensing deals that allows the licensor to license out their technology for the development of a product candidate.

Figure 3: Molecular diagnostics partnering by deal type since 2009
























Source: Current Agreements, 2014

Oncology is a popular area for molecular diagnostic dealmaking with over 200 deals signed since 2009.

Figure 4: Molecular diagnostics partnering by therapeutic area since 2009



















Source: Current Agreements, 2014

As an emerging and exciting area for therapeutic intervention, molecular diagnostics deal making can have a high headline deal value. The following figure shows the leading molecular diagnostic deals by headline value of the deal when announced between 2009 and 2014.

Figure 5: Top diagnostic deals by value since 2009













Source: Current Agreements, 2014

Life sciences industries are banking hugely on the growth of diagnostics market. With more and more companies merging to enhance development of diagnostic therapeutics (Eg: Agilent Technologies acquiring Dako for $2.2 billion), partnering trends are going to see rapid changes in the future.  Source: Current Agreements, 2014

The recently updated Molecular Diagnostics Partnering Terms and Agreements report published by Current Partnering provides full details of over 300 molecular diagnostic deals announced since 2009 and includes average deal terms including headline, upfront, milestone and royalty rates, where available. In addition, the report provides details of deals broken down by deal type, stage of development, company A-Z and technology type. More details here


The above information has been abstracted from the following resources:

Shamini Thiagarajan



Read: more on molecular diagnostics deals in pharma, biotech, life science partnering deal news, insights and glossary

ViewOther technology type reports

Read article: Diagnostics partnering: recent life science trends 2009-2014

Related report: Diagnostics Partnering Terms and Agreements ; Companion Diagnostics Partnering Terms and Agreements

ViewCP Insight’s Partnering Scorecard – view top life science partnering deals by value

ViewCP Insight ‘s Journal – the latest deal trend infographics for life science deal making

SubscribeCurrent Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply